Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 3 | BMC Pulmonary Medicine

Fig. 3

From: Role of NAT10-mediated ac4C acetylation of ENO1 mRNA in glycolysis and apoptosis in non-small cell lung cancer cells

Fig. 3

ENO1 was a downstream regulatory target of NAT10-mediated ac4C acetylation in A549 and PC9 cell lines. A, Genes positively and negatively related to NAT10 were obtained using the Linkedomics database; The mRNA and protein levels of ENO1 in A549 and PC9 cell lines were detected by B, RT-qPCR and C, Western blot after NAT10 knockdown; Ac4C-RIP assay was performed to detect ENO1 ac4C expression in D, A549 and E, PC9 cell lines; Dual-luciferase reporter assay was used to evaluate the binding of NAT10 and ENO1 in F, A549 and G, PC9 cell lines; RNA stability assay was used to detect the existing NAT10 expression when actinomycin D treated at different time points (0, 8, 16, and 24 h) in H, A549 and I, PC9 cell lines. (n = 3). NAT10, N-acetyltransferase 10; RT-qPCR, reverse transcription-polymerase chain reaction; ENO1, α-enolase; NSCLC, non-small cell lung cancer; RIP, RNA immunoprecipitation; ac4C, N4-acetylcytidine

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us